Efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus and concurrent heart failure

doi:10.5246/jcps.2025.11.076

Abstract

Abstract:

This study focused on a specific cohort of patients with type 2 diabetes mellitus (T2DM) complicated by heart failure (HF), aiming to evaluate the differences in treatment efficacy and safety between the original research formulation and the centralized procurement version of empagliflozin. Conducted as a retrospective study, 406 hospitalized patients with T2DM and HF admitted to our hospital between June 2022 and June 2023 were recruited and divided into two groups: a control group and an observation group, based on the type of empagliflozin administered. Through the application of rigorous statistical methodologies, comprehensive data collection, systematic organization, and detailed analysis were performed for both groups. The findings revealed that, following treatment with the two types of empagliflozin, a significant difference was observed in creatinine clearance rate between the groups. However, no statistically significant changes were detected in other critical efficacy indicators, including fasting blood glucose, glycated hemoglobin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and glomerular filtration rate (GFR), before and after treatment. From an economic perspective, the observation group demonstrated a clear cost advantage, with both total drug expenditures and the specific cost of empagliflozin being significantly lower than those in the control group. In conclusion, for patients with T2DM and HF, the centralized procurement version of empagliflozin offered comparable efficacy and safety to the original research formulation, with the exception of differences in creatinine clearance rate. The significant cost advantage of the centralized procurement version highlighted its value in clinical drug selection and hospital pharmacy management. These findings underscored the importance of considering both clinical outcomes and economic factors in optimizing treatment strategies for real-world practice.

Key words: Type 2 diabetes mellitus, Heart failure, Empagliflozin, Efficacy, Safety

Supporting:

Ying Wang, Huan Yu, Tingting Yan, Wenfei Pan. Efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus and concurrent heart failure[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(11): 1024-1032.

Figures/Tables 6

Table 1. Comparison of gender, age, and BMI between the two groups of patients.

Table 2. Comparison of co-morbid diagnoses between the two groups of patients.

Table 3. Comparison of the medication situation of the "New Quadruple" between the two groups of patients.

Table 4. Comparison of the situation of concomitant anti-diabetic medications between the two groups of patients.

Table 5. Comparison of the changes in the two groups of patients before and after treatment.

Table 6. Comparison of the single-dose and cost of drugs between the two groups of patients (x ± s, Yuan).

References 14

[1]	Aguilar, D.; Deswal, A.; Ramasubbu, K.; Mann, D.L.; Bozkurt, B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am. J. Cardiol. 2010, 105, 373–377.
[2]	Chen, J.W.; Liu, P.Q. Effect of empagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus complicated by heart failure with preserved ejection fraction. Jiangsu Med. J. 2023, 49, 402–408.
[3]	Qiu, J.M.; Wang, D.F. Research status of empagliflozin in the treatment of type 2 diabetes mellitus. Clin. Focus. 2022, 37, 170–173.
[4]	Dunlay, S.M.; Givertz, M.M.; Aguilar, D.; Allen, L.A.; Chan, M.; Desai, A.S.; Deswal, A.; Dickson, V.V.; Kosiborod, M.N.; Lekavich, C.L.; McCoy, R.G.; Mentz, R.J.; Piña, I.L.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019, 140, e294–e324.
[5]	Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E.; Investigators, E.O. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015, 373, 2117–2128.
[6]	McMurray, J.; Adamopoulos, S.; Anker, S.; Auricchio, A.; Böhm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gómez-Sánchez, M.; Jaarsma, T.; Køber, L.; Lip, G.; Maggioni, A.; Parkhomenko, A.; Pieske, B.; Popescu, B.; Rønnevik, P.; Rutten, F.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P.; Voors, A.; Zannad, F.; Zeiher, A.; Bax, J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kirchhof, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Reiner, Ž.; Sechtem, U.; Sirnes, P.; Tendera, M.; Torbicki, A.; Vahanian, A.; Windecker, S.; Bonet, L.A.; Avraamides, P.; Ben Lamin, H.A.; Brignole, M.; Coca, A.; Cowburn, P.; Dargie, H.; Elliott, P.; Flachskampf, F.; Guida, G.F.; Hardman, S.; Iung, B.; Merkely, B.; Mueller, C.; Nanas, J.; Nielsen, O.; Ørn, S.; Parissis, J.; Ponikowski, P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. J. Heart Fail. DOI: 10.1093/eurjhf/hfs105.
[7]	Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Chin. J. Cardiovasc. Dis. 2018, 46, 760–789.
[8]	Wang, H.Y (Ed.). Nephrology (3rd Edition). Beijing: People’s Medical Publishing House. 2008.
[9]	American Diabetes Association Professional Practice Commitee. Improving care and promoting health in populations: Standards of care in Diabetes-2024. Diabetes Care. 2024, 47, S11–S19. DOI: 10.2337/dc24-S001.
[10]	Diabetes Branch of the Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2020 Edition). Chin. J. Diabetes. 2021, 13, 315–409.
[11]	Chinese College of Cardiovascular Physicians; Chinese Heart Failure Center Alliance; The Task Force for Expert Consensus Decision Pathway for Quadruple Pharmacotherapy Management of Chronic Heart Failure. Expert consensus on decision-making pathway for Quadruple Pharmacotherapy Management of chronic heart failure. Chin. Circ. J. 2022, 37, 769–781.
[12]	Office of the National Healthcare Security Administration. Notice on Strengthening the Supply Guarantee of Selected Products in Centralized Procurement of Medicines. YB Office Letter [2024]No.5. Source: https://www.xifeng.gov.cn/zwgk/zdlygk/ylbz_5741548/cgylfwjg_5741551/202404/t20240409_84163570.html.
[13]	Beijing Pharmacological Society; Chinese Pharmacists Association; Branch of Rational Drug Use and Comprehensive Evaluation; Chinese Association of Geriatric Research; China Intelligent Pharmacy Alliance. Expert consensus on Beijing’s medical institutions implemented the centralized drug procurement organized by the state. China Med. 2022, 17, 1601–1604.
[14]	Luo, N.T.; Yue, J.Y.; Zhou, R.J.; Jiang, B. The effects of the National Drug Pooled Procurement (NDPP) pilot program in China. J. Chin. Pharm. Sci. 2022, 31, 212–217.

[1]	Chengxia Gong, Hui Wang, Xiaoyun Shi, Wenwen Wang, Huiping Gong. Comparative effectiveness of sacubitril/valsartan versus valsartan in patients with newly diagnosed hypertensive acute heart failure [J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(5): 458-469.
[2]	Xingnong Xu, Doudou He, Lei Ma. Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs [J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 223-231.
[3]	Xiaotong Yu, Jing Wu, Qi Zhang, Jiamei Hong, Jing Yu, Zhu Guan, Yanhui Yin, Zhenjun Yang. Enhanced antitumor efficacy of fresh pig spleen extracts (PAT) encapsulated with cytidinyl and cationic lipid nanocomplexes [J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(1): 14-27.
[4]	Yuxuan Shen, Tianchang Wang, Hua Qiao, Qing Liang, Jingru Lv, Qing Xia. Modulation of tRNAGln decoding efficacy by metal ion binding and glutamine supply [J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(1): 28-40.
[5]	Ye Yuan, Zhenzhen Yang, Bo Yu, Xiuling Yang. Medication analysis and pharmacy service for a patient with heart failure in ischemic cardiomyopathy combined with appendage thrombosis [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(1): 63-68.
[6]	Hanchun Yang, Fei Cheng, Juanjuan Huang. Efficacy of eltrombopag on refractory primary immune thrombocytopenia and its effect on cellular immune function [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 736-743.
[7]	Changping Lin, Sanyue Wang, Yunguo Xue, Youliu Yu. The effects of midazolam combined with dezocine on laparoscopic appendectomy [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 207-213.
[8]	Yuanchao Zhu, Chen Chen, Xin Hu. Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 145-152.
[9]	Ye Yuan, Yanan Li, Qing Zhao, Bo Yu, Xiuling Yang. Evaluation of ceftriaxone dosing regimens based on PK/PD models and Monte Carlo simulations [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 382-388.
[10]	Meng Tong, Wei Zhan, Chengcheng Niu, Zemei Ge, Runtao Li, Xin Wang. Continuous-flow, one-pot synthesis of asymmetrical aromatic ureas from acids and amines via curtius rearrangement [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(12): 938-945.
[11]	Taixiang Gao, Feng Zhao, Liyao Shi, Rui Wang. Exploring the mechanism of Fu-Zi Decoction in treatment of chronic heart failure based on network pharmacology and molecular docking technology [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 705-715.
[12]	Rui Li, Yanru Kong. Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 692-698.
[13]	Xing Sun, Changyong Yang, Kan Lin, Caihong Zhou, Chen Liao, Limin Zhang, Xinsheng Jin, Langyong Mao, Hua Ying, Weikang Tao, Lianshan Zhang. Camrelizumab (SHR-1210), a humanized anti-PD-1 IgG4 mAb, exhibits superior anti-tumor activity and a favorable safety profile in preclinical studies [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(5): 393-408.
[14]	Chunxing Li, Yuanmin Zhu, Hua Liu, Zhao Xu. Efficacy of prokinetic drugs in combination with proton pump inhibitors versus proton pump inhibitors alone in the treatment of gastroesophageal reflux disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 347-356.
[15]	Yan Zhou, Hengwen Song, Zhichao Shao, Bomin Yin, Ximei Fu, Dianyou Xie, Lijun Wei. Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor, QHRD107 against acute myeloid leukemia [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 146-156.